Cerebral Palsy Stem Cell Therapy Abroad: A Guide for Families in the Netherlands & UAE
How families in the Netherlands and the United Arab Emirates can explore stem cell therapy for cerebral palsy abroad — with honest context on regulation at home, coordination with your child's rehabilitation team, travel, and realistic expectations.
Why Families in the Netherlands and UAE Look Abroad
Cerebral palsy is the most common cause of physical disability in childhood, and both the Netherlands and the United Arab Emirates offer strong rehabilitation infrastructure. Dutch families access coordinated care through paediatric rehabilitation centres (revalidatiecentra), physiotherapy, occupational therapy, and specialist paediatric neurology. Families in Dubai and Abu Dhabi access a growing network of private rehabilitation clinics, paediatric therapists, and specialist centres.
What is not available domestically as a routine, reimbursed pathway in either country is mesenchymal stem cell (MSC) therapy. This leads some parents to research treatment abroad as a possible adjunct to their child's rehabilitation. StemCell Longevita operates as an international patient coordination platform based in Istanbul, Turkey — we are not a treatment provider, we do not diagnose cerebral palsy, and we do not promise recovery. Our role is to give families honest information, assess whether a child may be a reasonable candidate, and coordinate access to GMP-standard care at an accredited partner hospital while keeping the home rehabilitation team informed.
This guide is written for the Dutch and Emirati context — the regulation you live under, how a treatment episode abroad fits alongside intensive rehabilitation, and the practical realities of travelling to Istanbul with a child who has complex mobility needs.
The Regulatory Picture at Home
Knowing why the pathway differs helps families make a grounded, realistic decision.
Netherlands (EU/EMA)
MSC therapy for cerebral palsy is not approved or reimbursed under EMA rules and is not part of routine Dutch rehabilitation care. Pursuing it abroad is a personal, out-of-pocket choice.
United Arab Emirates
The UAE supports regenerative medicine research, but CP is not an approved indication. Families typically travel while continuing their child's rehabilitation programme at home.
Turkey's Framework
Turkey regulates cell therapy through its Ministry of Health with GMP-certified processing. MSC therapy for CP is offered within an individually-assessed, adjunctive, non-curative framework.
Honest Positioning
MSC therapy does not cure cerebral palsy or reverse established brain injury. It is studied as a supportive option that must sit alongside — never replace — rehabilitation.
What MSC Therapy Targets in Cerebral Palsy
The research rationale focuses on the environment around injured brain tissue, not on regrowing lost function.
Anti-Inflammatory Signalling
MSCs are studied for their capacity to reduce chronic neuroinflammation that can persist after the original brain injury.
Neurotrophic Support
Through secreted factors, MSCs are being investigated for support of surviving neural tissue — a research-stage hypothesis, not established fact.
Plasticity Window
Any potential benefit is thought to work best when paired with intensive rehabilitation that drives the brain's natural plasticity.
Adjunct, Not Replacement
The goal is to complement physiotherapy and occupational therapy — the true engines of functional gains in CP.
Why Timing and Rehabilitation Matter
For cerebral palsy more than almost any other condition, rehabilitation is the decisive factor in functional progress. The published rationale for MSC therapy is not that cells alone produce gains, but that they may create a more favourable biological environment in which intensive, well-structured rehabilitation can work. This is why we insist that any family we coordinate for maintains — and ideally intensifies — physiotherapy and occupational therapy around the time of treatment.
Age and severity also matter. Early childhood is a period of high neural plasticity, and many of the cases studied involve younger children. That said, older children and even young adults with CP have their own rehabilitation goals, and suitability is always assessed individually rather than by age alone. We will give a Dutch or Emirati family an honest view of whether their child's specific profile aligns with the cases where any benefit has been reported.
Crucially, no one can promise a child will walk, talk, or gain a specific ability. Reported outcomes in early studies vary widely and are often modest — improvements in areas like muscle tone, spasticity, or fine-motor control in some children, and no measurable change in others. We provide this framing before any family commits to travel.
The Coordinated Patient Journey
From your first enquiry to follow-up back home, coordination happens in clear stages.
1. Remote Case Review
You share your child's diagnosis, GMFCS level, imaging, and rehabilitation history. A medical team reviews suitability before anything is booked.
2. Consultation in Your Language
Consultations in English and Dutch, with Arabic-speaking coordination for UAE families, so you fully understand what is proposed.
3. Travel & Treatment Window
A typical stay in Istanbul is 5–7 days, planned around your child's needs and, where possible, school holidays.
4. Treatment Episode
Care is delivered at a JCI-accredited partner hospital using GMP-processed cells, with paediatric-appropriate monitoring.
5. Structured Follow-Up
A 12-month telemedicine follow-up keeps your Dutch or Emirati rehabilitation team informed of what was done.
6. Family Support
A single coordinator supports your family throughout — important when travelling with a child who has complex mobility needs.
Travel from Amsterdam, Dubai & Abu Dhabi
Istanbul is well connected to both regions. For a child with mobility needs, accessibility and pacing are planned in advance.
From the Netherlands
- Direct flights Amsterdam (AMS) to Istanbul (IST): approximately 3.5 hours
- No visa required for Dutch citizens for short medical stays
- Minimal time difference — easier on a child's routine
- English and Dutch-speaking coordination throughout
- Wheelchair-accessible transfers and family accommodation arranged in advance
From the UAE
- Direct flights Dubai (DXB) & Abu Dhabi (AUH) to Istanbul: approximately 4.5 hours
- Straightforward entry for UAE residents and citizens
- One hour behind UAE time — easy adjustment for children
- Arabic-speaking coordination support available
- Accessible transport and halal, family-friendly accommodation on request
Cost Compared to Staying Home
Indicative figures only — every case is individually quoted after a medical review confirms suitability.
Working With Your Rehabilitation Team
In cerebral palsy, rehabilitation drives progress. MSC therapy must complement it — never replace it.
Is Your Child a Candidate?
Careful selection matters, and some enquiries are advised that treatment is not appropriate.
Frequently Asked Questions
Related Stem Cell Treatments
Explore Care Coordination for Your Country
Trattamenti correlati
Malattia di Parkinson
Mira a rallentare la progressione e a sostenere i neuroni che producono dopamina.
Scopri di piùSclerosi multipla
Mira a regolare la risposta immunitaria e a sostenere la salute della guaina mielinica.
Scopri di piùTerapia per l'autismo
Può sostenere la funzione neurologica e ridurre l'infiammazione.
Scopri di piùCoordinamento Internazionale dei Pazienti
StemCell Longevita opera come piattaforma di coordinamento internazionale dei pazienti. Mettiamo in contatto i pazienti con istituzioni mediche autorizzate che offrono applicazioni di medicina rigenerativa dopo valutazione medica e nel rispetto dei quadri normativi applicabili. Tutte le decisioni e le procedure mediche sono condotte esclusivamente da professionisti sanitari autorizzati. StemCell Longevita non fornisce direttamente trattamenti medici.
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as medical advice. Stem cell therapy is an evolving field, and outcomes may vary by individual. The treatments described on this site have not been fully evaluated or approved by the FDA or equivalent regulatory bodies in all jurisdictions.
The FDA has not approved stem cell applications for most conditions listed on this website. Results mentioned are based on clinical observations, published research, and patient-reported outcomes. Individual results may vary and no specific outcomes are assured for any individual patient.
L'inclusione di pubblicazioni scientifiche su questo sito non implica approvazione normativa o risultati clinici garantiti. Alcune applicazioni possono essere considerate sperimentali a seconda dell'indicazione e della giurisdizione.
Always consult with a qualified healthcare professional before making any medical decisions. Do not disregard professional medical advice or delay seeking treatment based on information found on this website.